Article Text

SAT0220 Malignancy Risk is Increased in Patients with Systemic Sclerosis
  1. T. Kaşifoglu1,
  2. N. S. Yaşar Bilge1,
  3. F. Yıldız2,
  4. G. Özen3,
  5. Y. Pehlivan4,
  6. N. Yılmaz5,
  7. F. Tarhan6,
  8. S. Yılmaz7,
  9. A. Küçük8,
  10. H. Emmungil9,
  11. S. Koca10,
  12. M. Çınar11,
  13. C. Korkmaz1,
  14. H. Direskeneli3,
  15. D. Arslantaş12,
  16. E. Erken2,
  17. G. Can6,
  18. M. Özmen6,
  19. E. Gonullu1,
  20. B. Kısacık4,
  21. K. Aksu13,
  22. Ö. Karadağ5
  1. 1Eskişehir Osmangazi University, Division of Rheumatology, Eskişehir
  2. 2Çukurova University, Division of Rheumatology, Adana
  3. 3Marmara University, Division of Rheumatology, İstanbul
  4. 4Gaziantep University, Division of Rheumatology, Gaziantep
  5. 5Diyarbakır State Hospital, Rheumatology Division, Diyarbakır
  6. 6İzmir Katip Çelebi University, Division of Rheumatology, İzmir
  7. 7Selçuk University, Division of Rheumatology
  8. 8Necmettin Erbakan University, Division of Rheumatology, Konya
  9. 9Ege University, Division of Rheumatology, İzmir
  10. 10Fırat University, Division of Rheumatology, Elazığ
  11. 11Gulhane Military Academy Shcool of Medicine, Division of Rheumatology, Ankara
  12. 12Eskişehir Osmangazi University, Department of Public Health, Eskişehir
  13. 13Ege University, Division of Rheumatology, İzmir, Turkey


Background Systemic sclerosis (SSc) is an autoimmune connective tissue disease with multisystem involvement. An increased incidence of cancer in SSc patients compared with general population has been reported in several reports (1, 2).

Objectives Our aim was to determine the most common malignancies and to investigate the possible risk factors for development of malignancy in patients with SSc.

Methods Between March 2011 and December 2012, 340 SSc patients from 11 centers were included to the study. Datas of the patients were obtained by evaluating medical records retrospectively. Possible risk factors for development of malignancy were compared among patients with and without malignancy.

Results Total 340 patients with SSc were evaluated. Of 314 (92.4 %) patients were female and 26 (7.6 %) were male. The mean age was 48.86±11.51. Of the 25 patients had 19 different types of malignancy. Bladder cancer was the most common type of cancer with 4 patients and was followed by breast cancer with 3 patients, cervix ca and over ca with 2 patients each. Squamoz cell skin ca, adenoca with an unknown origin, multiple myelom (MM), chronic myeloid leukemia, papillary tyroid ca, larynx ca, non-small cell lung ca, follicular type NHL, endometrium ca, colon ca, uterus ca, neuroendocrin tumor, glioblastoma multiforme and soft tissue sarcoma were diagnosed in 1 patient each. Cancer development did not show a correlation with age, sex, smoking, type and duration of the disease, autoantibodies, organ involvement, dose and duration of cyclophosphamide therapy.

Conclusions Male sex, older age, and diffuse cutaneous involvement is reported for higher risk of malignancy. Diffuse cutaneous invelvement was more frequent in patients with malignancy but there was not a statistically significant difference (84% vs 36%, p: 0.10). Lung, oropharingeal and hematologic malignancies are reported as the most common types of malignancies in patients with SSc whereas bladder and hormon related malignancies were the most common types in our study group. The 19 different types of malignancy in 25 patients shows that cancer may develop in any organ in patients with SSc. Continious screening of the patients during folow up period is necessary to detect tumor development early.


  1. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, Kuwana M, Yasuoka H, van den Hoogen F, Te Boome L, van Laar JM, Verbeet NL, Matucci-Cerinic M, Georgountzos A, Moutsopoulos HM. Mortalityin systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005 Jan;118(1):2-10.

  2. Olesen AB, Svaerke C, Farkas DK, Sørensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol. 2010;163(4):800- 6

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.